MEDRAD® MRXperion MR Injection System and MR Injection System Syringe Kit +2 more— 510(k) K262043

Substantially Equivalent

Bayer Medical Care, Inc.

FDA 510(k) clearance K262043 for MEDRAD® MRXperion MR Injection System and MR Injection System Syringe Kit +2 more, Substantially Equivalent on 2026-10-06. Applicant: Bayer Medical Care, Inc.. Device class: 2.

Summary

Bayer Medical Care's clearance covers the MEDRAD MRXperion MR Injection System and its syringe kit, the MEDRAD IS12 Module (IS12), and the MEDRAD Imaging Bulk Package Transfer Spike. Product code DXT is angiographic injectors and syringes.

Class II, 21 CFR 870.1650. The General Hospital review panel handled it as a Traditional 510(k); the record lists Cardiovascular as the classification panel.

Bayer Medical Care filed from Indianola, Pennsylvania. Review took 111 days (June 17 to October 6, 2026).

Clearance details

Device name as filed
MEDRAD® MRXperion MR Injection System and MR Injection System Syringe Kit; MEDRAD® IS12 Module (IS12); MEDRAD® Imaging Bulk Package Transfer Spike
Applicant
Bayer Medical Care, Inc.
Product code
Product code DXT
Device class
Class 2
Regulation
21 CFR 870.1650
Advisory panel
Cardiovascular
Date received
Decision date
Decision
Substantially Equivalent
Clearance type
Traditional
Location
Indianola, PA, US
Download summary PDFView on FDA.gov ↗

Recent devices under product code DXT

view all

More clearances from Bayer Medical Care, Inc.

view all

Adverse events under product code DXT

product code DXT
Death
39
Injury
242
Malfunction
463
Other
3
Total
747

Source: openFDA MAUDE database, through . Counts aggregate all devices under this product code, not just this specific clearance. Reports are submissions to FDA, not validated events. Search MAUDE directly →

Data sourced from openFDA. This site is unofficial and independent of the FDA.